PCSK9 and familial hypercholesterolemia: Inhibition of the interaction between PCSK9 and the LDLR with monoclonal antibodies (mAbs) targeting PCSK9 has a great potential for patients with hypercholesterolemia (from the high risk groups), including familial hypercholesterolemia, as well as in patients with statin intolerance.